Everything below concerns AOD-9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-23. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
=== Avionics === Pizhma-1 navigational system with OMEGA inputs. GPS transceivers and a TCAS fitted retroactively during the 1990s. Pizhma-1 can be used throughout the flight from departure terminal area to landing and taxi to stand. Pizhma-1 has full-time roll and yaw dampers. Airfield approach aids enable instrument landing system-coupled approaches to ICAO Category II weather minima. Other radio aids include VOR and DME receivers, a weather radar, and Warsaw Pact identification aids. Cockpit voice recorders and flight data recorders standard. Four GT-40PCh6 engine generators generate energy from the Kuznetsov NK-86. The APU or ground sources supply 200/115 V, 400 Hz current to the primary system or two secondary systems (36 V/400 Hz AC and 27 V DC). Recipients include high-lift devices, tailplane trim, deicing, galley lift (elevator) and interior services.
The protein component of AGPs is rich in the amino acids Proline (P), Alanine (A), Serine (S) and Threonine (T), also known as 'PAST', and this amino acid bias is one of the features used to identify them. AGPs are intrinsically disordered proteins as they contain a high proportion of disordering amino acids such as Proline that disrupt the formation of stable folded structures. Characteristic of intrinsically disordered proteins, AGPs also contain repeat motifs and post-translational modifications. Proline residues in the protein backbone can be hydroxylated to Hydroxyproline (O) depending on the surrounding amino acids. The 'Hyp contiguity hypothesis' predicts that when O occurs in a non-contiguous manner, for example the sequence 'SOTO', such as occurs in AGPs, this acts as a signal for O-linked glycosylation of large branched type II arabinogalactan (AG) polysaccharides. Sequences that direct AG glycosylation (SO, TO, AO, VO) are called AGP glycomotifs. All AGP protein backbones contain a minimum of 3 clustered AGP glycomotifs and an N-terminal signal peptide that directs the protein into the endoplasmic reticulum (ER) where post-translational modifications begin. Prolyl hydroxylation of P to O is fulfilled by prolyl 4-hydroxylases (P4Hs) belonging to the 2-oxoglutarate dependant dioxygenase family. P4H has been identified in both the ER and Golgi apparatus. The addition of the glycosylphosphatidylinositol (GPI)-anchor occurs in most but not all AGPs.
Exposure to PFAS, some of which are carcinogens or endocrine disruptors, has been linked to diseases and health conditions including cancers, ulcerative colitis, thyroid disease, suboptimal antibody response or decreased immunity, decreased fertility, hypertensive disorders in pregnancy, fetal and child developmental issues, obesity, and high cholesterol. Due to the health and environmental concerns associated with many PFAS, PFOS and PFOA were listed in the Stockholm Convention on Persistent Organic Pollutants in 2009 and 2019, respectively. However, it is challenging to assess the potential risks of all PFAS due to the large data-gaps in toxicity and physicochemical properties. With thousands of compounds used in various application, only a few have undergone comprehensive biological testing. In some jurisdictions, such as the European Union, further reductions and phase-outs of PFAS are planned. Several companies are voluntarily ending or planning to end the sale of PFAS and PFAS-containing products due to health and litigation concerns. However, major producers and users such as the United States, Israel, and Malaysia have not ratified the agreement and the chemical industry has lobbied governments to reduce regulations.
=== Tracking of Fusion Proteins === Many different fusion proteins have been created using EosFP and its engineered variants. These fusion proteins allow for the tracking of proteins within living cells while retaining complex biological functions like protein-protein interactions and protein-DNA interactions. Eos fusion constructs include those with recombination signal-binding protein (RBP) and cytokeratin. Studies have shown that it is favourable to attach the protein of interest to the N-terminal side of the EosFP label. These fusion constructs have been used to visualize nuclear translocation with androgen receptors, dynamics of the cytoskeleton with actin and vinculin and intranuclear protein movement with RBP.
Sources: en.wikipedia.org
=== United States === Prominent outdoor retailers in the United States include Dick's Sporting Goods, Eddie Bauer, Backcountry.com, Outdoor Voices, REI, Patagonia, Marmot, Moosejaw, Sierra, The North Face and L.L.Bean.
Glucose transporter type 4 (GLUT4), also known as solute carrier family 2, facilitated glucose transporter member 4, is a protein encoded, in humans, by the SLC2A4 gene. GLUT4 is the insulin-regulated glucose transporter found primarily in adipose tissues and striated muscle (skeletal and cardiac). GLUT4 is distinctive because it is predominantly stored within intracellular vesicles, highlighting the importance of its trafficking and regulation as a central area of research. The first evidence for this glucose transport protein was provided by David James in 1988. The gene that encodes GLUT4 was cloned and mapped in 1989. At the cell surface, GLUT4 permits the facilitated diffusion of circulating glucose down its concentration gradient into muscle and fat cells. Once within cells, glucose is rapidly phosphorylated by glucokinase in the liver and hexokinase in other tissues to form glucose-6-phosphate, which then enters glycolysis or is polymerized into glycogen. Glucose-6-phosphate cannot diffuse back out of cells, which also serves to maintain the concentration gradient for glucose to passively enter cells.
==== Plants ==== Plant genome studies have revealed the existence of protein isovariants within the actin family of genes. Within Arabidopsis thaliana, a model organism, there are ten types of actin, six profilins, and dozens of myosins. This diversity is explained by the evolutionary necessity of possessing variants that slightly differ in their temporal and spatial expression. The majority of these proteins were jointly expressed in the tissue analysed. Actin networks are distributed throughout the cytoplasm of cells that have been cultivated in vitro. There is a concentration of the network around the nucleus that is connected via spokes to the cellular cortex, this network is highly dynamic, with a continuous polymerization and depolymerization.
Flutamide has been found to be equal to slightly more potent than cyproterone acetate and substantially more potent than spironolactone as an antiandrogen in bioassays. This is in spite of the fact that hydroxyflutamide has on the order of 10-fold lower affinity for the AR relative to cyproterone acetate. Hydroxyflutamide shows about 2- to 4-fold lower affinity for the rat and human AR than does bicalutamide. In addition, whereas bicalutamide has an elimination half-life of around 6 days, hydroxyflutamide has an elimination half-life of only 8 to 10 hours, a roughly 17-fold difference. In accordance, at dosages of 50 mg/day bicalutamide and 750 mg/day flutamide (a 15-fold difference), circulating levels of flutamide at steady-state have been found to be approximately 7.5-fold lower than those of bicalutamide. Moreover, whereas flutamide at this dosage has been found to produce a 75% reduction in prostate-specific antigen levels in men with prostate cancer, a fall of 90% has been demonstrated with this dosage of bicalutamide. In accordance, 50 mg/day bicalutamide has been found to possess equivalent or superior effectiveness to 750 mg/day flutamide in a large clinical trial for prostate cancer. Also, bicalutamide has been shown to be 5-fold more potent than flutamide in rats and 50-fold more potent than flutamide in dogs. Taken together, flutamide appears to be a considerably less potent and efficacious antiandrogen than is bicalutamide.
==== Opposition to the Patriot Act ==== Sanders was a consistent critic of the Patriot Act. As a member of the House, he voted against the original Patriot Act legislation. After its 357–66 passage in the House, he sponsored and voted for several subsequent amendments and acts attempting to curtail its effects and voted against each reauthorization. In June 2005, he proposed an amendment to limit Patriot Act provisions that allow the government to obtain individuals' library and book-buying records. The amendment passed the House by a bipartisan majority but was removed on November 4 of that year in House–Senate negotiations and never became law.
Sources: en.wikipedia.org
=== High background === Strong antibody concentrations, inadequate blocking, inadequate washing, and excessive exposure time during imaging can result in a high background in the blots. A high background in the blots could be avoided by fixing these issues.
== External links == An Extremely Detailed Map of the 2024 Election from The New York Times "Misinformation Dashboard: Election 2024. A tool tracking the topics and tactics of 2024 election misinformation". News Literacy Project. 2024. Retrieved September 30, 2024. Dovere, Edward-Isaac (November 6, 2024). "Where Harris' campaign went wrong". CNN. Retrieved November 7, 2024. "The Choice 2024: Harris vs. Trump". Frontline. Season 43. Episode 2. September 24, 2024. PBS. WGBH. Retrieved November 28, 2024. "The VP Choice: Vance vs. Walz". Frontline. Season 43. Episode 3. October 8, 2024. PBS. WGBH. Retrieved November 28, 2024.
== History == The Diet of Hungary (Hungarian: Országgyűlés) was a legislative institution in the medieval kingdom of Hungary from the 1290s, and in its successor states, Royal Hungary and the Habsburg kingdom of Hungary throughout the Early Modern period. The name of the legislative body was originally "Parlamentum" during the Middle Ages, the "Diet" expression gained mostly in the Early Modern period. It convened at regular intervals with interruptions during the period of 1527 to 1918, and again until 1946. In 1608, a bicameral legislature was enacted as the Royal Hungarian Diet, dividing the main board and the lower board (the board of envoys). Members of the main board (the upper house) were the high nobles and high priests (archbishops and bishops). The lower board was attended by representatives of the common nobility, clergy and civil order: elected representatives of the noble county, delegates of the free royal cities and representatives of the lower Church representatives. Approximately 10% of the total voting age population could vote for the elected delegates of the lower board (5% county nobility, 5% residents of free royal cities). The election of the noble delegates (1 delegate from each county) took place in the county delegate elections, after a long, noisy, courtier campaign, at the county hall. Delegates received voting instructions from county assemblies. The parliament consisted of about 500 people in the 17th–18th centuries.
== Fascial dynamics == Deep fascia is less extensible than superficial fascia. It is essentially avascular, but is richly innervated with sensory receptors that report the presence of pain (nociceptors); change in movement (proprioceptors); change in pressure and vibration (mechanoreceptors); change in the chemical milieu (chemoreceptors); and fluctuation in temperature (thermoreceptors). Deep fascia is able to respond to sensory input by contracting; by relaxing; or by adding, reducing, or changing its composition through the process of fascial remodeling. Fascia may be able to contract due to the activity of myofibroblasts which may play a role in wound healing. The deep fascia can also relax. By monitoring changes in muscular tension, joint position, rate of movement, pressure, and vibration, mechanoreceptors in the deep fascia are capable of initiating relaxation. Deep fascia can relax rapidly in response to sudden muscular overload or rapid movements. Golgi tendon organs operate as a feedback mechanism by causing myofascial relaxation before muscle force becomes so great that tendons might be torn. Pacinian corpuscles sense changes in pressure and vibration to monitor the rate of acceleration of movement. They will initiate a sudden relaxatory response if movement happens too fast. Deep fascia can also relax slowly as some mechanoreceptors respond to changes over longer timescales. Unlike the Golgi tendon organs, Golgi receptors report joint position independent of muscle contraction. This helps the body to know where the bones are at any given moment.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.